Display options
Cite
Wunder A, Thiele A, Koslowski M, et al. Nuclear imaging to support anti-inflammatory drug discovery and development. Q J Nucl Med Mol Imaging. 2014;
Wunder, A., Thiele, A., Koslowski, M., Gantner, F., & Niessen, H. (2014). Nuclear imaging to support anti-inflammatory drug discovery and development. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., .
Wunder, A, et al. "Nuclear imaging to support anti-inflammatory drug discovery and development." The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... vol. (2014).
Wunder A, Thiele A, Koslowski M, Gantner F, Niessen H. Nuclear imaging to support anti-inflammatory drug discovery and development. Q J Nucl Med Mol Imaging. 2014 May 15; Epub 2014 May 15. PMID: 24829127.
Copy Download .nbib Format: NLM
Share it on

Q J Nucl Med Mol Imaging. 2014 May 15; Epub 2014 May 15.

Nuclear imaging to support anti-inflammatory drug discovery and development.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

A Wunder, A Thiele, M Koslowski, F Gantner, H Niessen

Affiliations

  1. Boehringer Ingelheim Pharma GmbH & Co. KG. Translational Medicine & Clinical Pharmacology, Biberach an der Riss, Germany - [email protected].

PMID: 24829127

Abstract

Nuclear medicine contributes important tools to support antiinflammatory drug discovery and development in many ways. The support provided is manifold: new molecular entities (NME, either small molecules or biologics) labeled with radioisotopes can be applied in animal models and humans to measure biodistribution, target engagement, and pharmacokinetics. In addition, nuclear imaging techniques can be used to select or enrich the patient populations in clinical trials, to assess disease activity, target status and distribution and to quantify response to therapeutic interventions. In the first part of this review we will outline how nuclear imaging techniques can be applied to support informed decision making in drug development. In the second part, we will briefly highlight the use of nuclear imaging of inflammation in drug development in selected diseases, specifically rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), atherosclerosis (ATS) and as an emerging topic cancer.

Publication Types